Literature DB >> 28703880

Performance of prognostic scores and staging systems in predicting long-term survival outcomes after surgery for intrahepatic cholangiocarcinoma.

Stefan Buettner1,2, Boris Galjart2, Jeroen L A van Vugt2, Fabio Bagante1, Sorin Alexandrescu3, Hugo P Marques4, Jorge Lamelas4, Luca Aldrighetti5, T Clark Gamblin6, Shishir K Maithel7, Carlo Pulitano8, Georgios A Margonis1, Matthew Weiss1, Todd W Bauer9, Feng Shen10, George A Poultsides11, J Wallis Marsh12, Jan N M IJzermans2, Bas Groot Koerkamp2, Timothy M Pawlik1,13.   

Abstract

INTRODUCTION: We sought to validate the commonly used prognostic models and staging systems for intrahepatic cholangiocarcinoma (ICC) in a large multi-center patient cohort.
METHODS: The overall (OS) and disease free survival (DFS) prognostic discriminatory ability of various commonly used models were assessed in a large retrospective cohort. Harrell's concordance index (c-index) was used to determine accuracy of model prediction.
RESULTS: Among 1054 ICC patients, median OS was 37.7 months and 1-, 3-, and 5-year survival, were 78.8%, 51.5%, and 39.3%, respectively. Recurrence of disease occurred in 454 (43.0%) patients with a median DFS of 29.6 months. One-, 3- and 5- year DFS were 64.6%, 46.5 % and 44.4%, respectively. The prognostic models associated with the best OS prediction were the Wang nomogram (c-index 0.668) and the Nathan staging system (c-index 0.639). No model was proficient in predicting DFS. Only the Wang nomogram exceeded a c-index of 0.6 for DFS (c-index 0.602). The c-index for the AJCC staging system was 0.637 for OS and 0.582 for DFS.
CONCLUSIONS: While the Wang nomogram had the best discriminatory ability relative to OS and DFS, no ICC staging system or nomogram demonstrated excellent prognostic discrimination. The AJCC staging for ICC performed reasonably, although its overall discrimination was only modest-to-good.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  intrahepatic cholangiocarcinoma; prognostic staging; recurrence; risk factors; survival

Mesh:

Substances:

Year:  2017        PMID: 28703880     DOI: 10.1002/jso.24759

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  9 in total

1.  The Limitations of Standard Clinicopathologic Features to Accurately Risk-Stratify Prognosis after Resection of Intrahepatic Cholangiocarcinoma.

Authors:  Fabio Bagante; Katiuscha Merath; Malcolm H Squires; Matthew Weiss; Sorin Alexandrescu; Hugo P Marques; Luca Aldrighetti; Shishir K Maithel; Carlo Pulitano; Todd W Bauer; Feng Shen; George A Poultsides; Olivier Soubrane; Guillaume Martel; B Groot Koerkamp; Alfredo Guglielmi; Endo Itaru; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2018-01-19       Impact factor: 3.452

2.  A combined Cox and logistic model provides accurate predictive performance in estimation of time-dependent probabilities for recurrence of intrahepatic cholangiocarcinoma after resection.

Authors:  Seogsong Jeong; Guijuan Luo; Qiang Gao; Jing Chen; Xiaolong Liu; Liangqing Dong; Yongjie Zhang; Feng Shen; Qingbao Cheng; Chengjun Sui; Jingfeng Liu; Hongyang Wang; Qiang Xia; Lei Chen
Journal:  Hepatobiliary Surg Nutr       Date:  2021-08       Impact factor: 7.293

3.  Prognostic factors for patients with mass-forming intrahepatic cholangiocarcinoma: A case series of 68 patients.

Authors:  Jian Feng; Bin Liang; Hang-Yu Zhang; Zhe Liu; Kai Jiang; Xiang-Qian Zhao
Journal:  World J Gastrointest Surg       Date:  2022-05-27

Review 4.  The focus clinical research in intrahepatic cholangiocarcinoma.

Authors:  Yinghui Song; Mengting Cai; Yuhang Li; Sulai Liu
Journal:  Eur J Med Res       Date:  2022-07-11       Impact factor: 4.981

5.  A blood-based noninvasive miRNA signature for predicting survival outcomes in patients with intrahepatic cholangiocarcinoma.

Authors:  Yuma Wada; Mitsuo Shimada; Yuji Morine; Tetsuya Ikemoto; Yu Saito; Hideo Baba; Masaki Mori; Ajay Goel
Journal:  Br J Cancer       Date:  2022-01-25       Impact factor: 9.075

Review 6.  Strategies for the delay of surgery in the management of resectable hepatobiliary malignancies during the COVID-19 pandemic.

Authors:  S Bennett; K Søreide; S Gholami; P Pessaux; C Teh; E Segelov; H Kennecke; H Prenen; S Myrehaug; D Callegaro; J Hallet
Journal:  Curr Oncol       Date:  2020-10-01       Impact factor: 3.677

7.  Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.

Authors:  Rui Zhang; Qi Li; Jialu Fu; Zhechuan Jin; Jingbo Su; Jian Zhang; Chen Chen; Zhimin Geng; Dong Zhang
Journal:  BMC Cancer       Date:  2021-02-03       Impact factor: 4.430

8.  Aggressive local treatment for recurrent intrahepatic cholangiocarcinoma-Stereotactic radiofrequency ablation as a valuable addition to hepatic resection.

Authors:  Eva Braunwarth; Peter Schullian; Moritz Kummann; Simon Reider; Daniel Putzer; Florian Primavesi; Stefan Stättner; Dietmar Öfner; Reto Bale
Journal:  PLoS One       Date:  2022-01-04       Impact factor: 3.240

9.  A simple scoring system to estimate perioperative mortality following liver resection for primary liver malignancy-the Hepatectomy Risk Score (HeRS).

Authors:  Dimitrios Moris; Brian I Shaw; Cecilia Ong; Ashton Connor; Mariya L Samoylova; Samuel J Kesseli; Nader Abraham; Jared Gloria; Robin Schmitz; Zachary W Fitch; Bryan M Clary; Andrew S Barbas
Journal:  Hepatobiliary Surg Nutr       Date:  2021-06       Impact factor: 7.293

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.